BRIEF—Kite shares new data on CAR T cell therapy

Kite, a Gilead Sciences company, will share four posters that add to the growing body of evidence to support the clinical use of its chimeric antigen receptor (CAR) T-cell therapy portfolio, at the 7th European CAR T-cell Meeting, 6-8 February 2025, Strasbourg, France.

Data from Italy demonstrate Kite’s commitment to changing patient outcomes for people living with difficult-to-treat blood cancers through manufacturing excellence and support programs.

“As the leader in CAR-T cell therapy, Kite is pleased to add to the important scientific exchange during the 7th European CAR T-Cell Meeting, with a focus on improving outcomes for people living with difficult-to-treat blood cancers,” said Dan Tovar, interim head of medical affairs, Kite, Australia, Canada and Europe (ACE) Region, adding: “These presentations reinforce the importance of support programmes and infrastructure needed to meet the ongoing unmet need for patients and improve healthcare system resources.”